Moderna-Merck mRNA vaccine cuts melanoma recurrence 42% — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Intismeran autogene reduced the risk of disease recurrence in melanoma patients by 42% compared with standard treatment in a large clinical trial conducted by Moderna and Merck.
- Moderna and Merck's trial drew support from oncologists, who called the results an important advance because patients lived significantly longer without their cancer returning.
- Merck and Moderna's individualized therapy attacks neoantigens — the unique mutations found in a patient's tumor — rather than a single shared cancer target.
- The mRNA platform behind the vaccine is the same technology that enabled the rapid development of vaccines against Covid-19.
- The trial result may usher in a new wave of treatments for other cancer types, though experts are debating how broadly applicable the individualized technology is.
Why it matters: The 42% recurrence reduction gives melanoma patients and oncologists a therapy that measurably extends time without cancer returning relative to standard treatment. Experts' split over how far the individualized neoantigen method travels into other tumors keeps that wider ambition from being settled by this trial alone.
Ask SkimNews
